Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis
Latest Information Update: 13 May 2022
Price :
$35 *
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms GO-COLITIS
- Sponsors Merck Sharp & Dohme Corp.
- 01 Nov 2017 Results (n=140) of the 12-week follow-up of patients in clinical response at week 54, presented at the 25th United European Gastroenterology Week.
- 01 Nov 2017 Results of the maintenance phase (n=140) presented at the 25th United European Gastroenterology Week
- 26 May 2016 Status changed from active, no longer recruiting to completed.